On June 24th, Glon Hui | Alnylam Pharmaceuticals Inc. (ALNY) rose by more than 33.7%, the largest intraday increase since August 2022, as the company achieved success with its therapy vutrisiran (Amvuttra) for the deterioration of ATTR heart disease (requiring hospitalization) and resulting in death, meaning that the company's best-selling products are expected to create a new situation, and the company's CEO Yvonne Greenstreet said that the prospects for widespread use will give the company an opportunity to generate (at least) billions of dollars. PTC Therapeutics, Caribou Biosciences, Protherna Plc., argenx ADR, and bluebird Bio all rose by at least 9%, while Taysha Gene fell more than 5.2%, Savara fell 6.44%, and BridgeBio Pharma fell 17.43%.
纳斯达克生物科技指数涨超2%，心脏病疗法概念股Alnylam涨约34%领跑
Nasdaq Biotechnology Index rose more than 2%, Alnylam, a concept stock in heart disease treatment, rose about 34% leading the way.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.